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Summary 
Yeast ubiquinone or coenzyme Q6 (Q6) is a redox active lipid with a crucial role in the 
mitochondrial electron transport chain. At least nine proteins (Coq1p-9p) participate in Q6 
biosynthesis from 4-hydroxybenzoate (4-HB). We now show that the mitochondrial 
ferredoxin Yah1p and the ferredoxin reductase Arh1p are required for Q6 biosynthesis, 
probably for the first hydroxylation of the pathway. Conditional Gal-YAH1 and Gal-ARH1 
mutants accumulate 3-hexaprenyl-4-hydroxyphenol and 3-hexaprenyl-4-aminophenol. Para-
aminobenzoic acid (pABA) is shown to be the precursor of 3-hexaprenyl-4-aminophenol and 





C ring-labeled Q6, a result which identifies pABA as a new precursor of Q6 
and implies an additional NH2-to-OH conversion in Q6 biosynthesis. Our study identifies 





Coenzyme Q (ubiquinone or Q) is a lipophilic organic molecule composed of a 
substituted benzoquinone and a polyprenyl chain containing 6 units in Saccharomyces 
cerevisiae (Q6) and 10 in humans (Q10). Q has a well known role as an electron carrier in the 
mitochondrial respiratory chain and also functions as a membrane soluble antioxidant 
(Bentinger et al., 2007). Moreover, Q  has been implicated in modulating the permeability of 
transition pores (Fontaine and Bernardi, 1999) and  is an obligatory cofactor for the proton  
transport function of uncoupling proteins (Echtay et al., 2001).  
4-hydroxybenzoate (4-HB) is the long-known aromatic precursor of the benzoquinone 
ring of Q (Olson et al., 1963; Rudney and Parson, 1963). Cells synthesize Q from 4-HB and 
from dimethylallyl diphosphate and isoprenyl diphosphate, the building blocks for the 
polyprenyl chain. After covalent linkage of the polyprenyl tail to 4-HB to form 3-polyprenyl-
4-hydroxybenzoate, a total of 1 decarboxylation, 3 hydroxylation and 3 methylation reactions 
at the aromatic ring are necessary to yield Q (Figure 1). Current knowledge of the genes 
involved in Q biosynthesis in eukaryotes is mostly derived from the work carried out on yeast 
by C. Clarke (Tran and Clarke, 2007). So far, 9 genes (COQ1-9) have been characterized as 
essential for Q biosynthesis in yeast but only 6 gene products have been assigned a catalytic 
role (Figure 1)(Kawamukai, 2009). All S. cerevisiae COQ1-9 genes have human relatives. 
Primary Q10 deficiency, a rare recessive disorder, has now been linked to mutations in five 
genes: PDSS1 (Mollet et al., 2007) and PDSS2 (Lopez et al., 2006; Mollet et al., 2007) ,which 
are the relatives of COQ1 ; COQ2 (Mollet et al., 2007); COQ9 (Duncan et al., 2009) and 
ADCK3/CABC1 the relative of COQ8 (Lagier-Tourenne et al., 2008; Mollet et al., 2008).  
Genetic and biochemical data have shown in yeast that a multi-protein Q biosynthetic 
complex forms and associates with the mitochondrial inner membrane on the matrix side 
(Tran and Clarke, 2007). The proteins Coq3, Coq4, Coq6, Coq7 and Coq9 are part of the Q 
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biosynthetic complex (Tran and Clarke, 2007) and steady state levels of these proteins are 
strongly decreased in any coq null mutants that lack one of the COQ genes (Tran and Clarke, 
2007). This explains why yeast coq mutants rarely accumulate biosynthetic Q intermediates 
that may be diagnostic of the altered reaction in a particular mutant. Indeed, yeast null coq3 to 
coq9 mutants accumulate the same early intermediate 3-hexaprenyl-4-hydroxybenzoate 
(HHB) (Figure 1). Only selective mutations altering the activity of a Coq protein without 
drastically affecting assembly of the Q biosynthetic complex may lead to accumulation of 
intermediates different from HHB. Only 2 such intermediates have been unambiguously 
identified and linked to a mutation in a COQ gene: 5-demethoxyubiquinone (DMQ6) 
accumulates in two coq7 mutants, L237Stop and E233K (Padilla et al., 2004), and  3-
hexaprenyl-4,5-dihydroxybenzoate accumulates in an uncharacterized coq3 mutant strain 
(Clarke et al., 1991). The rare occurrence of intermediates diagnostic of the defective step in 
Q biosynthesis largely explains why the order of reactions modifying the aromatic ring of 4-
polyprenyl-3 hydroxybenzoate is still speculative (Tran and Clarke, 2007).  
Coq6p and Coq7p are two mono-oxygenases that function of Q biosynthesis.  Coq7p 
hydroxylates DMQ6 (Padilla et al., 2004; Tran et al., 2006) and Coq6p may catalyse one or 
both of the two remaining hydroxylation steps (Gin et al., 2003) (Figure 1). Mono-oxygenases 
are widely distributed proteins that catalyze incorporation of one oxygen atom into substrates. 
Dioxygen is the source of the oxygen atom and mono-oxygenases usually employ a transition 
metal (iron, copper) or an organic cofactor (flavin, pterin) to mediate dioxygen activation at 
their active site. This activation requires two electrons which are provided by a reductant. 
NAD(P)H can directly reduce the flavin cofactor of flavoprotein mono-oxygenases whereas 
reduction of the heme iron in cytochrome P450 type oxygenases is accomplished by an 
associated reductase (Ballou et al., 2005; Munro et al., 2007). The mammalian electron 
transport machinery of mitochondrial cytochrome P450 consists of two proteins, an NADPH-
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ferredoxin reductase called adrenodoxin reductase (AdxR) and a [2Fe-2S] ferredoxin called 
adrenodoxin (Adx). To date, proteins resembling mitochondrial cytochrome P450 mono-
oxygenase have not been found in yeast, yet yeast expresses a mitochondrial ferredoxin 
(Yah1p) and a mitochondrial ferredoxin reductase (Arh1p) which are homologues of Adx and 
AdxR.  
The Yah1p/Arh1p system is located in the mitochondrial matrix and is required for 
viability (Barros and Nobrega, 1999; Manzella et al., 1998). Yah1p and Arh1p play an 
essential role in the biogenesis of Fe-S clusters (Lange et al., 2000; Li et al., 2001) and of 
heme A (Barros et al., 2002), an indispensable cofactor of cytochrome c oxidase. Cox15p 
which catalyzes the conversion of heme O to heme A is the likely recipient of electrons 
transferred by Yah1p (Barros et al., 2002) whereas the recipient is still unknown for the 
biogenesis of Fe-S clusters. Conserved motifs in the primary sequence of Coq6p and Coq7p 
predict that these two mono-oxygenases employ a flavin and a di-iron cofactor respectively 
(Gin et al., 2003; Stenmark et al., 2001). The oxidized flavin of Coq6p is a two-electron 




) center of Coq7p will also accept two 
electrons but one at a time. Therefore the putative direct two-electron reduction of the flavin 
of Coq6p by hydride transfer from NAD(P)H is not applicable to the di-iron center of Coq7p. 
The in vivo source of electrons used by Coq7p is still unknown and we hypothesized that the 
Yah1p/Arh1p system may fulfill this role.  
In this work, we show that the Yah1p/Arh1p system is essential for yeast Q6 synthesis. 
Cells depleted for Yah1p or Arh1p accumulate specific intermediates of Q6 upstream of 
DMQ6, the substrate of Coq7p. The accumulation of these early intermediates pointed to the 
involvement of Yah1p/Arh1p in the first hydroxylation reaction of Q6 biosynthesis. 
Surprisingly, one of the intermediates accumulated in Yah1p-depleted cells contains an amine 
group. This observation led us to show that para-aminobenzoic acid (pABA) is the precursor 
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of this intermediate and that pABA enters the Q biosynthetic pathway at the prenylation 
reaction catalyzed by Coq2p. Moreover, labeling experiments proved that pABA is an in vivo 
precursor of the benzoquinone ring of Q6. This new, unexpected role of pABA has been 
overlooked since the discovery of 4-HB as the precursor of the benzoquinone ring of Q more 




The mitochondrial ferredoxin Yah1p and its associated reductase Arh1p are essential 
for Q6 biosynthesis  
In order to test the possible role of the mitochondrial ferredoxin Yah1p in Q6 biosynthesis, we 
used the strain Gal-YAH1 in which the native YAH1 promoter was replaced by the GAL10 
promoter (Lange et al., 2000). Therefore, the expression of the essential YAH1 gene in the 
Gal-YAH1 strain is under the control of a galactose-inducible promoter (Lange et al., 2000). 
When YAH1 expression was repressed by cultivating the Gal-YAH1 strain in a glucose-
containing medium, we noted a strong depletion of the Q6 content of the cells together with 
that of DMQ6 (Figure 2A). Q6 and DMQ6 were detected electrochemically after separation of 
cell lipid extracts by HPLC. Surprisingly, we detected an additional electroactive compound 
eluting at around 610 seconds which was absent from the galactose-grown cells (Figure 2A). 
The striking decrease of Q6 does not result from dying cells because the cells were viable at 
the end of the glucose culture as assessed by determining the colony forming units on 
galactose medium. Introduction of a plasmid carrying the YAH1 gene in the Gal-YAH1 strain 
restored wild-type Q6 levels in glucose-grown cells and abolished the accumulation of the 
electroactive compound (Figure 2B). To verify that the [2Fe-2S] cluster of Yah1p was 
required for Q6 generation, we constructed mutant alleles of Yah1p in which conserved Fe-S 
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cysteine ligands (C103 and C106) are mutated to alanine (Figure S1) (Xia et al., 1996). The 
electrochromatograms of extracts from glucose-grown Gal-YAH1 strains containing an empty 
vector and from C103A or C103-106S mutants of Yah1p were similar, with an accumulation 
of the newly detected metabolite, showing that these cysteines are essential for Yah1p 
function (Figure 2B and data not shown). The Fe-S center of Yah1p is reduced by electrons 
provided by the ferredoxin reductase Arh1p which is also an essential protein (Manzella et al., 
1998). In order to corroborate the observation that Yah1p is required for Q6 biosynthesis, we 
generated a Gal-ARH1 strain in which the expression of ARH1 is repressed by growth in 
glucose medium. After growth of the Gal-ARH1 strain in glucose medium, Arh1p was 
undetectable in purified mitochondria but Yah1p steady state level was only mildly decreased 
(Figure 2C). These mitochondria showed little Q6 and accumulated the electroactive 
compound found in Yah1p-depleted mitochondria (Figure 2D). Altogether, these results show 
that the absence of a functional ferredoxin / ferredoxin reductase system strongly depletes 
cellular and mitochondrial levels of Q6 and promotes the accumulation of a novel compound.  
 
A strain deficient in Yah1p accumulates 3-hexaprenyl-4-aminophenol, a product derived 
from the Q6 biosynthetic pathway 
We attempted to identify the origin and nature of the electroactive compound 
accumulating in Yah1p-deficient cells and found that it is different from DMQ6, the only 
intermediate of Q6 biosynthesis observed by electrochemical detection so far. Deletion of 
COQ5 or COQ7, two genes essential for Q6 biosynthesis, abolishes formation of Q6 and 
results in the accumulation of HHB because many Coq proteins of the Q biosynthetic 
complex are unstable in these mutants (Figure 1)(Tran and Clarke, 2007). Deletion of COQ5 
or COQ7 in the Gal-YAH1 strain prevented the accumulation of the electroactive compound 
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upon depletion of Yah1p (Figure 3A and data not shown). This result suggests that the 
electroactive compound is part of the Q6 pathway and is formed downstream of HHB.  
In order to determine whether the compound is produced during the Q6 biosynthetic 
pathway or is a degradation product of Q6, we exploited a strain which accumulates mostly 
DMQ6 instead of Q6. This strain contains a chromosomal insertion of a sequence coding for a 
triple hemagglutinin (3HA) epitope tag on the 3’end of COQ7. The presence of the 3HA 
epitope on the C terminus of Coq7p likely causes the partial inactivation of the protein as 
evidenced by the accumulation of large amounts of DMQ6 as compared to Q6 (Figure 3B).  
Depletion of Yah1p in a Gal-YAH1 COQ7-3HA strain resulted in a strong decrease of DMQ6 
and still promoted the accumulation of the electroactive compound eluting at around 610 s 
(Figure 3B). This result demonstrates that this compound is not a degradation product of Q6 
and strongly suggests that it originates from Q6 biosynthesis at a step prior to the 
hydroxylation of DMQ6 catalyzed by Coq7p.  
We purified the compound in its reduced form, analyzed it by high resolution mass 
spectrometry and obtained a m/z ratio of 518.43610 (M+H
+
).  The molecular mass was 
submitted to different chemical formula prediction software; C36H55NO was the elemental 
composition which fitted best (M= C36H55NO: 517.42836; observed mass, 517.42828; ppm, 
0.2) when C,H,N,O,P,S atoms were included in the calculation. In order to determine if the 
C36H55NO molecule contains a hexaprenyl moiety like Q6, we obtained two fragmentation 
spectra of the 518.4 molecular ion (M+H
+
) on different spectrometers. The fragments at m/z 
122 and 162 are consistent with carboxyaminotropylium and carboxyaminopyrilium ions, 
respectively (Figure S2A). Tropylium and pyrilium ions are typically observed upon 
fragmentation of Q6 (m/z 197 and 237) and DMQ6 (m/z 167 and 207) (Padilla et al., 2004). 
The fragmentation observed on the spectrum in Figure S2B is consistent with the successive 
loss of methine, methylene or methyl groups of the hexaprenyl chain, the lightest fragment 
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(162.0915) corresponding to C10H12NO. Both fragmentation spectra are indicative of the 
presence of a hexaprenyl chain in the C36H55NO molecule.  
We next characterized the purified C36H55NO molecule by NMR spectroscopy. The 
resulting 
1
H NMR spectrum shows well-defined peaks with some of them easily attributable 
to the hexaprenyl moiety (methyl, methylene and vinylic protons) (Figure 3C and 
experimental procedures). The aromatic region shows three massifs (6.67 to 6.61 ppm, 6.57 to 
6.54 ppm and 6.52 to 6.46 ppm) of equal intensity all situated at rather high field for aromatic 
protons (Figure 3D). These results strongly suggest the presence of three electro-donating 
substituents on the aromatic ring. Moreover, the observed multiplicity associated with the 
value of the coupling constants unambiguously establishes both meta and para substitutions. 
Finally, the aromatic region of the spectrum was compared to that of the commercially 
available 3-methyl-4-aminophenol (Figure 3D). Both spectra were almost super-imposable, 
with identical pattern and coupling constants and slightly different chemical shifts. The UV-
visible absorption spectra of the reduced and oxidized forms of the purified compound and of 
3-methyl-4-aminophenol show identical absorbance maxima (Figure S2C and S2D). All these 
results unambiguously identify 3-hexaprenyl-4-aminophenol as the electroactive compound 
accumulated in Yah1p-deficient cells (Figure 3E). For the sake of simplicity, the numbering 
of the aromatic carbon atoms of the different Q6 intermediates throughout this manuscript will 
be as in Figure 3E.  
 
pABA is the precursor of 3-hexaprenyl-4-aminophenol and competes with 4-HB for 
prenylation by Coq2   
The presence of a nitrogen atom in a product synthesized in vivo by the Q6 
biosynthetic pathway was surprising. Indeed, C, H and O atoms are the only constituents of 
the different intermediates of Q biosynthesis described to date (Figure 1). Para-aminobenzoic 
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acid (pABA) is structurally close to para-hydroxybenzoic acid (4-HB), the precursor of the 
aromatic ring of Q (Figure 1). We therefore hypothesized that the 3-hexaprenyl-4-
aminophenol synthesized in the Yah1p-deficient strain might originate from pABA. The 
accumulation of 3-hexaprenyl-4-aminophenol increased in the Gal-YAH1 strain upon addition 
of pABA to YP-glucose (YPD) medium (Figure 4A) showing that pABA is the precursor of 
3-hexaprenyl-4-aminophenol. We also consistently detected more 3-hexaprenyl-4-
aminophenol when the Gal-YAH1 strain was cultured in glucose synthetic complete (SC-2% 
glu) medium compared to YPD (compare Figure 4A and 4B). This is likely because pABA is 
an ingredient of synthetic medium at 0.2mg/L.  
pABA being a precursor of 3-hexaprenyl-4-aminophenol suggested that pABA is 
prenylated by the polyprenyl transferase Coq2p, which is known to prenylate 4-HB. 
Decreased levels of 3-hexaprenyl-4-aminophenol were observed in the Gal-YAH1 strain when 
4-HB was added to the culture medium (Figure 4B) suggesting a competition between pABA 
and 4-HB for prenylation by Coq2p. Addition of 3,4-dihydroxybenzoic acid was without an 
effect on the accumulation of 3-hexaprenyl-4-aminophenol (data not shown).  
A coq5 strain accumulates HHB, the product of the prenylation of 4-HB catalyzed by 
Coq2p (Figure 1)(Tran and Clarke, 2007).  Esterification of HHB with diazomethane 
stabilizes HHB and facilitates its detection by mass spectrometry (Poon et al., 1995). 3-
Hexaprenyl-4-hydroxybenzoic acid methylester (HHBme) (M= C38H56O3: 560.42291; 
observed mass, 560.42113; ppm, 3.2) was detected spectroscopically eluting at 620 s in 
chromatograms of diazomethane-treated extracts of the coq5 strain (Figure 4C), and was 
found to be absent from extracts of the WT strain or from untreated extracts (data not shown). 
pABA supplementation increased the accumulation of  3-hexaprenyl-4-aminobenzoic acid 
methylester (HABme) (M= C38H57NO2: 559.43890; observed mass, 559.43931; ppm, 0.7) 
eluting at 570 s in diazomethane-treated extracts of the coq5 strain (Figure 4C). HABme was 
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also absent from extracts of the WT strain or from untreated extracts (data not shown). It is 
apparent in Figure 4C that pABA supplementation increases HABme and decreases HHBme 
whereas 4-HB supplementation increases HHBme and decreases HABme. This shows that 
pABA and 4-HB are competing substrates for the prenylation reaction catalyzed by Coq2p.  
 
Concomitant accumulation of 3-hexaprenyl-4-hydroxyphenol and 3-hexaprenyl-4-
aminophenol  by the Yah1p-deficient strain. 
SC medium contains pABA which efficiently competes with 4-HB for the prenylation 
reaction. In order to check if a compound originating from 4-HB may form within the Yah1p-
deficient strain, we cultured the Gal-YAH1 strain in YPD instead of SC medium (Figure 2A). 
Together with 3-hexaprenyl-4-aminophenol at 610 s, we detected an electroactive compound 
eluting at 800 s in extracts of the Gal-YAH1 strain cultured in YPD (Figure 5A and Figure 
4A). The purified compound yielded a pseudo-molecular ion at m/z 519.41962 (M+H
+
) upon 
high resolution mass spectrometry analysis. This value is consistent with a chemical formula 
C36H54O2 (M= C36H54O2: 518.41235; observed mass, 518.4118; ppm, 1.1). The fragmentation 
spectrum supports the presence of a hexaprenyl tail in the molecule with fragments 
corresponding to loss of methine, methylene or methyl groups of the hexaprenyl chain (Figure 
S3A). UV-Vis spectra of the C36H54O2 molecule are similar to the ones of methyl-1,4-
benzoquinone (Figure S3B and S3C respectively). These results in addition to the fact that the 
C36H54O2 molecule is not formed in either the Gal-YAH1 coq5 or Gal-YAH1 coq7 cells 
(data not shown) strongly suggest that 3-hexaprenyl-4-hydroxyphenol is the electroactive 
compound eluting at 800 s (Figure 5B).  
This conclusion was further substantiated by the finding that 4-HB is the precursor of 
3-hexaprenyl-4-hydroxyphenol. Indeed, addition of 4-HB to YPD medium increased 3-
hexaprenyl-4-hydroxyphenol and decreased 3-hexaprenyl-4-aminophenol in the Yah1p-
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deficient strain (Figure 5C).  In contrast, addition of pABA increased the quantity of 3-
hexaprenyl-4-aminophenol as noted earlier (Figure 4A), but also decreased the production of 
3-hexaprenyl-4-hydroxyphenol (Figure 5C). This competition between pABA and 4-HB for 
the formation of 3-hexaprenyl-4-aminophenol and 3-hexaprenyl-4-hydroxyphenol parallels 
the one observed for the biosynthesis of 3-hexaprenyl-4-aminobenzoic acid   and 3-
hexaprenyl-4-hydroxybenzoic acid (Figure 4C).  
 
pABA is a precursor of Q6 
We have shown that 3-hexaprenyl-4-aminophenol and 3-hexaprenyl-4-aminobenzoic 
acid originate from pABA, suggesting that pABA enters the Q6 biosynthetic pathway (Figure 





C)-toluene in three steps (Figure S4 and Supplemental experimental 





C6-labeled 3-hexaprenyl-4-aminophenol at m/z 524.4 (data not 
shown). A WT strain was cultured in YPD supplemented with 2mg/L of U-(
13
C)-pABA and 
Q6 was purified. The mass spectrum of this purified Q6 showed two peaks of comparable 
abundance at m/z 591.4 and 597.4 (Figure 6A), corresponding respectively to unlabeled Q6 
and 
13
C ring-labeled Q6. This result clearly shows that pABA is a precursor of Q6 in yeast. In 
order for pABA to be converted into Q6, the amine group must be replaced by an hydroxyl 
group during the Q6 biosynthetic pathway after the formation of 3-hexaprenyl-4-
aminobenzoate.  The COQ7-3HA strain mostly accumulated DMQ6 instead of Q6 (Figure 3B). 
The mass spectrum of DMQ6 purified from the COQ7-3HA strain grown in YPD 
supplemented with 2mg/L of U-(
13
C)-pABA displayed two main ions (M+H
+
) m/z 561.43036 
and 567.45111, which correspond to unlabeled DMQ6 (M= C38H56O3: 560.42294; observed 
mass, 560.42254; ppm, 0.7) and to 
13






observed mass, 566.44329; ppm, 0.4) respectively. This result demonstrates that the NH2-to-
OH substitution occurs prior to the hydroxylation of DMQ6 by Coq7p, the penultimate step of 
Q6 biosynthesis.  
We next cultured the W303 WT strain in synthetic medium lacking pABA. To our 
surprise, cells grown in pABA-free medium accumulated 8 to 10 fold less Q6 than cells grown 
in rich (YP) medium or in synthetic medium (Figure 6B). Addition of 0.2 mg/L of pABA to 
pABA-free medium yields synthetic medium and restored normal levels of Q6 (Figure 6B). 
pABA and 4-HB were equally efficient to support Q6 synthesis when added to pABA-free 
medium. These results illustrate our conclusion that pABA is a precursor of Q6 and support 
the idea that most of the Q6 synthesized by yeast grown in synthetic medium actually 
originates from the pABA present in the growth medium. In order to determine whether S. 
cerevisiae uses endogenous pABA for Q6 biosynthesis, we cultured the Gal-YAH1 strain in 
pABA-free medium containing 2% galactose and then in pABA-free medium containing 2% 
glucose. 3-Hexaprenyl-4-aminophenol was detected in cell lipid extracts (data not shown), 
showing that endogenously synthesized pABA enters the Q biosynthetic pathway.  
 
Discussion  
In this work, we show that the mitochondrial ferredoxin Yah1p and its reductase 
Arh1p, the yeast homologues of mammalian Adx and AdxR, are essential for Q biosynthesis 
in yeast. Strains depleted for any of these two essential proteins have a strongly reduced 
content of Q6 and accumulate 3-hexaprenyl-4-aminophenol and 3-hexaprenyl-4-
hydroxyphenol (Figure 5C). 3-hexaprenyl-4-aminophenol results from the prenylation of 
pABA by Coq2p whereas prenylation of 4-HB, the long known ring precursor of Q, will 
ultimately produce 3-hexaprenyl-4-hydroxyphenol (Figure 7 paths 1 and 4, respectively). 
pABA and 4-HB differ only by one substituent of benzoic acid, an amine or an hydroxyl 
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group, and both molecules originate in E. coli and yeast from chorismate, a product of the 
shikimate pathway. In agreement with our results, pABA has previously been shown to be 
prenylated by orthologs of Coq2p in E. coli and rat as evidenced by the observation of 3-
polyprenyl-4-aminobenzoic acid (Hamilton and Cox, 1971) (Alam et al., 1975). pABA can 
therefore enter the Q biosynthetic pathway in many organisms but are these organisms 
capable of  converting 3-polyprenyl-4-aminobenzoic acid into Q? Our work clearly shows 
that, in yeast, 3-hexaprenyl-4-aminobenzoic acid is converted to Q6 since addition of U-(
13
C)-
pABA to the growth medium of WT yeast strain promotes the biosynthesis of 
13
C6 labeled Q6 
(Figure 6A and Figure 7 path 2). pABA is likely not a precursor of Q in E. coli because a 
mutant strain deficient in chorismate synthetase activity synthesized Q upon supplementation 
of the growth medium with 4-HB but not with pABA, despite the formation of 3-polyprenyl-
4-aminobenzoic acid (Hamilton and Cox, 1971). Our results with yeast warrant a thorough 
investigation to determine whether mammalian cells can convert pABA into Q. In vitro 
experiments by Rudney and collaborators on rat liver demonstrated that pABA is converted to 
3-polyprenyl-4-aminobenzoic acid and suggested that this compound was further modified 
although not into Q (Alam et al., 1975). Therefore pABA has been considered an inhibitor of 
Q biosynthesis in mammals but only a limited decrease of Q was observed in cancer cells 
upon culture in a high concentration of pABA (Brea-Calvo et al., 2006).  
In view of our observation that Q6 levels drop dramatically when yeast is cultured in 
pABA-free medium, it is reasonable to postulate that most of the Q6 produced by yeast 
cultured in SC medium originates from the pABA present in this growth medium.  Our results 
suggest that in pABA-free medium the rate-limiting step of Q6 biosynthesis is the availability 
of the ring precursors of Q, 4-HB and pABA. Endogenous levels of these molecules allow the 
synthesis of only 1.4 pmoles of Q6/mg of wet cells under our non-repressive culture 
conditions. One can then question the physiological significance of the high levels of Q6 (12-
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16 pmoles of Q6/mg of wet cells) synthesized by yeast grown in SC medium or rich medium. 
Actually, several authors have shown that only a small percentage of the Q6 synthesized in 
these growth media is sufficient to sustain respiratory growth (Mollet et al., 2008; Tran et al., 
2006), suggesting that, under normal conditions, Q6 is in vast excess for its function as an 
electron carrier in the respiratory chain. Our results also provide a possible explanation as to 
why, contrary to E. coli, mutants affecting 4-HB synthesis may not abrogate yeast Q6 
biosynthesis and therefore not result in a respiratory deficient phenotype. Previously, authors 
have speculated that yeast may produce 4-HB by multiple ways; from chorismate via the 
chorismate pyruvate-lyase reaction similar to the E. coli pathway and from tyrosine like in 
higher eukaryotes (Clarke, 2000). However, none of the enzymes responsible for these 
reactions have been identified in yeast. The fact that pABA can be used in Q6 biosynthesis 
like 4-HB and that pABA is present in standard yeast culture media imply that pABA may 
support biosynthesis of Q6  in a yeast mutant blocked for the synthesis of 4-HB when cultured 
in standard conditions.  
The conversion of pABA into Q6 suggests an additional step in Q6 biosynthesis: the 
replacement of the amine by an hydroxyl group at C4 (Figure 7 path 2). This reaction 
certainly takes place downstream of the hexaprenylation reaction catalyzed by Coq2p since 3-
hexaprenyl-4-aminobenzoic acid was detected in a coq5 strain (Figure 4C). The formation of 
13
C6-DMQ6 upon supplementation of the growth medium with U-(
13
C)-pABA proves that the 
C4 aromatic NH2-to-OH conversion occurs prior to the formation of DMQ6. The 
accumulation of 3-hexaprenyl-4-aminophenol in the Yah1p-depleted strain suggests that this 
reaction occurs after the C1 hydroxylation step. Alternatively, the presence of the amine 
group at this stage may simply result from the lack of hydroxylation of the adjacent C5 
position. Indeed, based on the example of bacterial anthranilate and aniline dioxygenases, 
which catalyze the conversion of aromatic amines into ortho-catechols (Beharry et al., 2003) 
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(Ang et al., 2007), the NH2-to-OH substitution on C4 may occur together with the 
hydroxylation on C5. The NH2-to-OH conversion reaction is chemically challenging and 
future studies will have to elucidate this newly evidenced process in Q6 biosynthesis. 
What is the role of Yah1p/Arh1p in Q6 biosynthesis? Deficiency in any of these two 
proteins results in accumulation of 3-hexaprenyl-4-amino/hydroxyphenol. In order to form 3-
hexaprenyl-4-amino/hydroxyphenol from 3-hexaprenyl-4-amino/hydroxybenzoic acid, the 
decarboxylation and hydroxylation at position 1 must occur without hydroxylation of C5 
(Figure 7, paths 1 and 4). Therefore the most upstream reaction of the Q6 biosynthetic 
pathway to be inhibited in the absence of Yah1p/Arh1p is the C5 hydroxylation of 3-
hexaprenyl-4-amino/hydroxybenzoic acid. The identity of the mono-oxygenase that catalyzes 
the C5 hydroxylation is currently unknown. Coq6p has been initially proposed to catalyze 
either the C5 or C1 hydroxylations or both (Gin et al., 2003). Our results strongly argue for 
the involvement of Coq6p in only one of the two reactions since the C1 hydroxylation still 
proceeds in the Yah1p/Arh1p-depleted strains whereas the C5 hydroxylation does not. Coq6p 
sequence contains conserved motifs characteristic for flavin-dependent mono-oxygenases 
such as 4-hydroxybenzoate hydroxylase (Gin et al., 2003). Reduction of the FAD cofactor at 
the active site of 4-hydroxybenzoate hydroxylase has been extensively studied and shown to 
proceed via a direct hydride transfer from NADPH (Ballou et al., 2005). By analogy, 
NAD(P)H is the likely electron donor to Coq6p, making the hydroxylation catalyzed by Coq6 
independent of the Yah1p/Arh1p reducing system. We thus propose that the C1 hydroxylation 
which is unaffected by depletion of Yah1p/Arh1p is catalyzed by Coq6p (Figure 7). This 
point is difficult to prove since a coq6 strain, like the other coq3 to coq9 null mutants, 
accumulates only HHB because of the instability of the Q biosynthetic complex (Gin et al., 
2003; Hsieh et al., 2007). The involvement of Coq6p in the C1 hydroxylation implies that the 
C5 hydroxylation is catalyzed by an unknown oxygenase which may require an electron 
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transport machinery like Yah1p/Arh1p. This scenario would explain why the C5 
hydroxylation is abrogated upon depletion of Yah1p or Arh1p.  
How to explain that the reactions after the C1 hydroxylation (C2 methylation by 
Coq5p, C6 hydroxylation by Coq7p and O6 methylation by Coq3p) do not take place in the 
Yah1p-depleted strain (Figure 7 path 1 and 4)? Yah1p is likely not directly required for the 
methylation reactions since: (i) methylations are non redox reactions (ii) they employ S-
Adenosyl-Methionine (SAM) as a methyl donor, a cofactor whose synthesis is cytosolic and 
does not require Fe-S containing enzymes whose maturation is generally dependent on Yah1p 
(Lange et al., 2000). The two O-methylation reactions can not proceed because of the lack of 
the two corresponding hydroxylations (C5 and C6). The absence of methylation at C2 may be 
explained in that the C2 carbon will be insufficiently enriched in electrons for an efficient 
nucleophilic attack to the methyl group of SAM in the absence of the methoxy group on C5. 
Alternatively, the absence of this methoxy group may prevent substrate binding and 
recognition by Coq5p. Finally, we envision at least two reasons that could explain the 
inactivity of Coq7p in the absence of Yah1p/Arh1p. On the one hand, Coq7p may not bind a 
substrate that lacks the C5 methoxy group and the C2 methyl group. On the other hand, 
Yah1p/Arh1p may provide electrons for the reduction of the di-iron center of the mono-
oxygenase Coq7p, a scenario which was the founding hypothesis of this study.  We could not 
gain any information on this point since Yah1p/Arh1p is required for the hydroxylation of 3-
hexaprenyl-4-amino/hydroxybenzoic acid, a reaction upstream of the hydroxylation of DMQ6 
which is catalyzed by Coq7p. Further work is needed to test if Yah1p/Arh1p is the 
physiological reducing system of Coq7p. Answering of this question will probably require the 
development of an in vitro assay for Coq7p function, a task highly challenging given that, in 
vivo, Coq7p is part of the Q biosynthetic complex (Tran and Clarke, 2007).   
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In conclusion, our study has unraveled that pABA serves as a precursor of Q6 similar 
to 4-HB whose role in Q biosynthesis was identified more than forty years ago. We also 
demonstrated that the yeast Adx/AdxR homologs Yah1p/Arh1p are required for the first 
hydroxylation reaction of the yeast Q6 biosynthetic pathway, which represents a new function 
for these proteins. In the light of these results, it seems important to evaluate whether these 




Coenzyme Q is a redox active lipid that functions in electron transport chains in cellular 
membranes and also has an important antioxidant function. Q is a prenylated benzoquinone 
which biosynthesis starts with the assembly of a polyprenyl chain and its conjugation to 4-
HB, the precursor of the benzoquinone moiety (Turunen et al., 2004). Here we demonstrate 
that yeast can convert pABA into Q making of pABA a new precursor of Q, like the long-
known 4-HB. Our finding thus implies that an aromatic NH2-to-OH conversion must occur to 
synthesize Q from pABA. The reducing system formed by the mitochondrial ferredoxin 
Yah1p and its associated reductase Arh1p is essential for Fe-S cluster biosynthesis (Lange et 
al., 2000; Li et al., 2001). This study identifies a new function for Yah1p and Arh1p in Q 
biosynthesis in yeast.  Studies on yeast have provided the basis for the elucidation of the 
eukaryotic biosynthesis of Q.  Sequence identity to yeast genes and complementation of yeast 
mutants have allowed the characterization of genes implicated in human Q biosynthesis.  
Mutations in five human genes have been shown to cause primary Q deficiency, which results 
in encephalomyopathy and severe infantile multisystemic disease. It will be of interest to 





Yeast strains and culture conditions: Yeast strains used in this study are listed in Table S1. 
Yeast strains were transformed using lithium acetate. A 3HA epitope tag was inserted on the 
3’ end of COQ7 ORF by PCR as described previously (Longtine et al., 1998) to create the 
COQ7-3HA strain. This strain was crossed with the Gal-YAH1 gene to isolate the COQ7-3HA 
Gal-YAH1 strain by selecting the corresponding markers after tetrad dissection. The coq5∆ 
Gal-YAH1 and coq7∆ Gal-YAH1 strains were obtained in a similar way. In Gal-ARH1, the 
upstream region from ARH1 was exchanged for the galactose-inducible GAL-L promoter by 
PCR mediated DNA replacement (Janke et al., 2004).Yeast media were supplemented with 
either 2% glucose or 2% galactose. Synthetic medium consisted in 1.7g/L YNB and 5g/L 
ammonium sulfate and
 
the appropriate nutrients to complement strains auxotrophies. 
Synthetic complete (SC) medium was obtained by adding 2g/L Drop-out mix Synthetic minus 
Ade, His, Leu, Trp, Ura (US Biological) to synthetic medium. YNB without pABA and folate 
was from MP Biomedicals and was supplemented with 5ug/L folate. Rich YP medium was 
prepared as described (Sherman, 2002). Gal-YAH1 and Gal-ARH1 strains were maintained 
and precultured on galactose medium. Depletion of Yah1p was accomplished by diluting 300 
fold the preculture into glucose containing medium and growing the cells for 18 hours at 
30°C. Depletion of Arh1p required two subsequent dilutions in glucose medium.  
Plasmids : YAH1 ORF with its own promoter (380bp) and terminator (150bp) was cloned into 
pRS416 using XhoI and SacI. This vector served as a template to generate the C103A and 
C103,106S mutants by site directed mutagenesis. Sequencing was used to confirm cloning 
products in all created vectors. The E. coli strain DH5 was used for plasmid DNA 
amplification.  
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Miscellaneous biochemical analysis: Isolation of yeast mitochondria and immunostaining 
were performed as described (Diekert et al., 2001) (Harlow and Lane, 1988).  
Lipid extraction and quantification of electroactive compounds by HPLC-ECD 
(electrochemical detection): Lipid
 




as described (Tran et al., 2006).100 uL glass beads, 50uL H2O and Q4 (used as an 
internal standard) were added to mitochondria (100ug mitochondrial proteins) or to cell 
pellets (40mg wet weight). Tubes were wrapped in foil and lipids were extracted
 
by adding 
0.6 mL methanol and 0.4 mL petroleum ether and by vortexing
 
for 3 minutes. The phases 
were separated by centrifugation (3 min
 
at 1000 × g, 4 °C). The upper petroleum ether layer 
was transferred
 
to a fresh tube. 0.4 mL petroleum ether was added to the
 
glass bead-methanol 
containing tube and the extraction was repeated 2 more times.  The petroleum ether layers 
were combined and dried under nitrogen. The lipids were resuspended
 
in 100 uL  mobile 
phase (98% methanol, 20mM lithium perchlorate) and aliquots were analyzed by reversed-
phase
 
high pressure liquid chromatography with a C18 column (Betabasic-18, 5 µm, 4.6 × 150 
mm, Thermo Scientific) at a flow rate of 1 ml/min. Quinones were quantified with an ESA
 
Coulochem II electrochemical detector and a 5011A analytical
 
cell (E1, –500 mV; E2, 500 
mV). Hydroquinones present
 
in samples were oxidized with a pre-column 5020 guard cell set 
in oxidizing
 
mode (E, +550 mV). The maximum output signal of the analytical electrode E2 
was set to +10V and was recorded by a 4 channel signal recorder USB10 (Velleman 
instruments). The Q4 external standard was used to correct for sample loss during the organic 
extraction based on its recovery (always greater than 85%).  
NMR analysis of 3-hexaprenyl-4-aminophenol: NMR spectra were recorded on a Bruker 
EMX 300 MHz spectrometer. 3-hexaprenyl-4-aminophenol: assignable protons: 
1
H NMR 
(CD3OD) 6.64 (d, 
3
J = 8.4 Hz, H2N-C-CH, 1H) , 6.55 (d, , 
4
J = 2.8 Hz, H2N-C-CH-CH-
C(OH)-CH, 1H), 6.49 (dd, 
3
J = 8.4 Hz, 
4
J = 2.8 Hz, H2N-C-CH-CH, 1H), 5.27 (t, 
3
J = 7.1 Hz, 
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Ar-CH2-CH, 1H), 5.12 (m, vinylic H, 5H), 3.21 (d, 
3
J = 7.2 Hz, benzylic H), 2.25-1.90 (m, 
vinylic CH2 and CH3) 
 
Esterification and analysis of 3-hexaprenyl-4-aminobenzoate and 3-hexaprenyl-4-
hydroxybenzoate: Dried lipid extracts from yeast cells (700mg wet weight) were 
resuspended in 400uL anhydrous diethyl ether.  150uL of diazomethane (0.2 M in diethyl 
ether) was added, the mixture was incubated for 8 minutes at room temperature and the 
reaction was quenched by adding 10uL of glacial acetic acid. Samples were dried under 
nitrogen and HPLC analysis was carried out as described for quinone content quantification 
except that the signal recorded was the absorbance at 273nm.  
Mass spectrometry 
For high resolution mass spectrometry analyses, samples in methanol were diluted in 
90% acetonitrile, 0.2% formic acid and were infused into the nanospray source of a discovery 
ORBITRAP instrument (Thermo Fischer Scientific) at a flow rate of 0.5uL min
-1
. The MS 
method used a scan range of 150-1600 m/z and was composed of MS and MS/MS events 
using both the Orbitrap as the analyzer (at a resolution of 30000) to get  high precision on the 
molecular and on the fragments ions. The CID fragmentation collision energy used was set to 
35 eV and the MS/MS scan range to 100-2000 m/z. QualBrowser from XCalibur was used to 
read the spectra.  
Analyses involving coupling of HPLC to mass spectrometry were performed with an 
series 1100 Agilent chromatographic system associated to SCIEX API 3000 triple 
quadrupolar mass spectrometer. Separation was performed on an octadecylsilyl ODB 
Uptisphere column (150×2 mm ID, 5 µm particle size, Montluçon, France), using a gradient 
of acetonitrile in 2 mM ammonium formate. MS2 spectra were obtained by selecting pseudo-
molecular ion in quadrupole 1 and fragmenting it in the collision cell. The fragmentation 
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Figure 1: Current model of the eukaryotic coenzyme Q biosynthetic pathway. The names 
of proteins and intermediates relevant to this study are for S. cerevisiae. The polyprenyl 
diphosphate tail is assembled from one dimethylallyl pyrophosphate and 5 isopentenyl 
pyrophosphate in yeast or 9 in humans. Prenylation of 4-hydroxybenzoate (4-HB) by Coq2 
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yields 3-hexaprenyl-4-hydroxybenzoate (HHB). 7 modifications of the aromatic ring are then 
needed to produce coenzyme Q6. 5-demethoxyubiquinone (DMQ6) is the substrate of the 
mono-oxygenase Coq7p. Reactions catalyzed by unidentified or putative proteins are marked 
with ?.  
 
Figure 2: The yeast ferredoxin/ferredoxin reductase system is required for Q6 
biosynthesis: A) Gal-YAH1 cells were cultivated for 18 hours in SC medium containing either 
2% galactose (gal) or 2% glucose (glu). Extracts of 10 mg (gal) and 20 mg (glu) of cells were 
analyzed by electrochemical detection coupled to HPLC (HPLC-ECD). Elution positions of 
the Q4 standard, of DMQ6 and Q6 and of the electroactive compound (?) accumulated in 
Yah1p-depleted cells are indicated on the electrochromatogram.    B) WT and Gal-YAH1 cells 
containing an empty vector (vec) or the YAH1 ORF were grown in SC-2% glucose for 18 
hours. Extracts of  8mg of cells were analyzed by HPLC-ECD. C) WT and Gal-ARH1 cells 
were cultivated for 40 h  in SC-2% glucose in order to deplete Arh1p to critical levels. 
Mitochondria were prepared and analysed for Arh1p and Yah1p by immunostaining. Porin 
(Por1p) served as a loading control. D) Mitochondrial extracts (50ug of mitochondrial 
proteins) were analyzed by HPLC-ECD. Mitochondria were purified from WT, Gal-YAH1 
and Gal-ARH1 cells grown in SC-2% glucose.  
 
Figure 3: 3-hexaprenyl-4-aminophenol is derived from Q6 biosynthesis A) Gal-YAH1 cells 
and Gal-YAH1 coq5 cells were inoculated from a culture in SC-2% galactose 0.4% glucose 
into SC-2% glucose and grown for 18 hours. Extracts of 30 mg of cells were analyzed by 
HPLC-ECD. B) WT, COQ7-3HA and Gal-YAH1 COQ7-3HA cells were grown in YPD for 12 
hours. Extracts of 45 mg (WT), 60 mg (COQ7-3HA) and 120 mg (Gal-YAH1 COQ7-3HA) of 
cells were analyzed by HPLC-ECD. C) 
1
H NMR spectrum of the purified C36H55NO molecule 
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in deuterated methanol. D) Superimposition of the aromatic regions of the 
1
H NMR spectrum 
of the purified C36H55NO molecule displayed in panel C and of the 
1
H NMR spectrum of 
commercial 3-methyl-4-aminophenol (3M4Aphe). E) Chemical structure of 3-hexaprenyl-4-
aminophenol and numbering of the aromatic carbon atoms used in the rest of the study. 
 
Figure 4: pABA and 4-HB compete for prenylation by Coq2p. A) 50 mg of Gal-YAH1 cells 
grown for 18 hours in YPD supplemented with pABA were extracted and analyzed by HPLC-
ECD. B) 30 mg of Gal-YAH1 cells grown for 18 hours in SC-2% glucose supplemented with 
4-HB were extracted and analyzed by HPLC-ECD. C) coq5 cells were grown in 30mL YPD 
with the indicated concentration of pABA or 4-HB. Lipid extracts were treated with 
diazomethane and analyzed by HPLC. The elution profile at 273nm and the elution position 
and chemical structure of 3-hexaprenyl-4-aminobenzoic acid methylester (HABme) and 3-
hexaprenyl-4-hydroxybenzoic acid methylester (HHBme) are shown. Areas of the peaks at 
273nm for HABme and HHBme are shown in the inset (A.U., arbitrary units).  
 
Figure 5: Yah1p-deficient cells also accumulate 3-hexaprenyl-4-hydroxyphenol. A) 20 mg 
of Gal-YAH1 cells grown for 18 hours in YPD were extracted and analyzed by HPLC-ECD. 
B) Chemical structure of 3-hexaprenyl-4-hydroxyphenol. C) 30 mg of Gal-YAH1 cells grown 
for 18 hours in YPD supplemented with 1 or 10mg/L 4-hydroxybenzoic acid (4-HB) or  para-
aminobenzoic acid (pABA) were extracted and analyzed by HPLC-ECD. 3-hexaprenyl-4-
aminophenol elutes at around 610 s and 3-hexaprenyl-4-hydroxyphenol at around 800 s and 
areas of the peaks are shown in the inset (A.U., arbitrary units).  
Figure 6: pABA is a precursor of Q6. A) Mass spectrum of Q6 purified from a W303 WT 
strain grown in YPD medium supplemented with 2mg/L of U-(
13
C)-pABA. B) The W303 WT 
strain was grown in synthetic medium, synthetic medium lacking pABA or rich (YP) medium, 
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with 2% galactose as a carbon source. Cells were harvested in late exponential growth phase 
and lipids were extracted. Q6 (pmoles per mg of wet weight cell pellet) was quantified by 
HPLC-ECD and DMQ6 represented less than 10% of Q6 in all samples.  Data are the average 
of at least 3 independent cultures and error bars represent the standard error of the mean.  
 
Figure 7: Dysfunction of the Q6 biosynthetic pathway in Yah1p/Arh1p-depleted yeast 
cells. R stands for the hexaprenyl chain. Reactions blocked in the absence of Yah1p/Arh1p 
are shown in red. The different series of reactions are numbered path 1 to 4. Coq2p catalyzes 
the hexaprenylation of pABA (blue) and 4-HB to form 3-hexaprenyl-4-aminobenzoic acid and 
3-hexaprenyl-4-hydroxybenzoic acid, respectively. In a WT strain, the conversion of 3-
hexaprenyl-4-aminobenzoic acid into Q6 requires the NH2-to-OH conversion on C4 which 
occurs prior to DMQ6 (path 2). The C5 hydroxylation of 3-hexaprenyl-4-
amino/hydroxybenzoic acid catalyzed by an unidentified oxygenase is blocked in the absence 
of Yah1p/Arh1p (path 2 and 3). In this case, the normal Q6 biosynthetic pathway (path 2 and 
3) branches off via decarboxylation of 3-hexaprenyl-4-aminobenzoic acid (path 1) and 3-
hexaprenyl-4-hydroxybenzoic acid (path 4). Coq6p then synthesize 3-hexaprenyl-4-
aminophenol (path 1, framed) and 3-hexaprenyl-4-hydroxyphenol (path 4, framed). 3-
hexaprenyl-4-amino/hydroxyphenol accumulate because Coq5p does not catalyze the C2 
methylation and Coq7p does not catalyze the C6 hydroxylation in the absence of 
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Supplemental information includes four figures, one table, supplemental experimental 
procedures and references: 
 
Figure S1 relates to the mutants of Yah1p in Figure 2B. 
Figure S2 corresponds to additional characterization of the compound displayed in Figure 3E. 
Figure S3 corresponds to additional characterization of the compound displayed in Figure 5B. 
Figure S4 shows the chemical synthesis of labeled pABA used in Figure 6A.  
Table S1 contains the yeast strains used in this study.  
Supplemental experimental procedures include the description of the chemical synthesis of 
labeled pABA (Figure S4) and the purification of 3-hexaprenyl-4-aminophenol (Figure 3E).  
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huFdx           -----------------------------------------SSS-------------EDK 6 
Yah1            MLKIVTRAGHTARISNIAAHLLRTSPSLLTRTTTTTRFLPFSTSSFLNHGHLKKPKPGEE 60 
                                                         *:*              :: 
 
huFdx           ITVHFINRDGETLTTKGKVGDSLLDVVVENNLDIDGFGACEGTLACSTCHLIFEDHIYEK 66 
Yah1            LKITFILKDGSQKTYEVCEGETILDIAQGHNLDMEG--ACGGSCACSTCHVIVDPDYYDA 118 
                :.: ** :**.  * :   *:::**:.  :***::*  ** *: ******:*.: . *:  
 
huFdx           LDAITDEENDMLDLAYGLTDRSRLGCQICLTKSMDNMTVRVPETVADARQSIDVGKTS 124 
Yah1            LPEPEDDENDMLDLAYGLTETSRLGCQIKMSKDIDGIRVALPQMTRNVNN-NDFS--- 172 
                *    *:************: ******* ::*.:*.: * :*: . :..:  *..    




















Figure S1: Sequence alignment of S. cerevisiae mitochondrial ferredoxin Yah1 and the 
human ferredoxin (huFdx). The alignment was generated using Clustalw. The conserved 
cysteines 52 and 55 shown to be important to coordinate the 2Fe-2S cluster in huFdx are 
pointed (Xia et al., 1996).  The corresponding cysteines 103 and 106 (in red) have been 
mutated in Yah1.  
 
Figure S2: Fragmentation spectra and UV-Vis spectra of the purified C36H55NO 
molecule. A) Fragmentation spectrum obtained on a SCIEX API 3000 mass spectrometer. 
The ions at m/z 122 and 162 correspond respectively to carboxyaminotropylium and 
carboxyaminopyrilium ions. B) Fragmentation spectrum obtained on a discovery ORBITRAP 
spectrometer. The fragments whose high resolution mass are indicated correspond to loss of 
methine, methylene or methyl groups of the hexaprenyl chain. C) A similar quantity of 
purified 3-hexaprenyl-4-aminophenol (3H4Aphe) was injected on the HPLC column with the 
precolumn electrode set at +550mV (ox) or -500mV (red). The UV-Vis spectra of the 
oxidized (ox) and reduced (red) forms of 3H4Aphe were recorded at the apex of the elution 
peak of the product.  The absorption maxima of the spectra are indicated. D) UV-Vis spectra 
of 1 nmole of 3-methyl-4-aminophenol (3M4Aphe) after chromatography on the HPLC 
column with the precolumn electrode set at +550mV (ox) or -500mV (red). 
 
Figure S3: Fragmentation spectrum and UV-Vis spectra of the purified C36H54O2 
molecule. A) Fragmentation spectrum obtained on a discovery ORBITRAP spectrometer. The 
fragments whose high resolution mass are indicated correspond to loss of methine, methylene 
or methyl groups of the hexaprenyl chain. B) UV-Vis spectra of a similar quantity of purified 
3-hexaprenyl-4-hydroxyphenol (3H4Hphe) after chromatography on the HPLC column with 
the precolumn electrode set at +600mV (ox) or -500mV (red). C) UV-Vis spectra of 1 nmole 
of methyl-1,4-benzoquinone (M1,4benzoQ) after chromatography on the HPLC column with 
the precolumn electrode set at +600mV (ox) or -1000mV (red). 
 
Figure S4: Chemical synthesis of U-(
13
C)-p-aminobenzoic acid. The detailed protocol is 
described in the supplemental experimental procedures.  
 
Table S1:  S. cerevisiae strains used in this study 
 
Strain Genotype Source 
W303 MATα ade2-1 his3-1,15 leu2-3,112 trp1-1, ura3-1 Invitrogen  
Gal-YAH1 W303 genotype, Gal-YAH1::LEU2 (Lange et al., 
2000) 
W303 coq5∆ W303 genotype coq5:: HIS3 (Barkovich et 
al., 1997) 
DY5113 (W303) MATa ade2-1 his3-1,15 leu2-3,112 trp1, ura3-1 (Keller et al., 
2005) 
COQ7-3HA DY5113 genotype COQ7-3HA::TRP1 This work 
COQ7-3HA gal-YAH1 DY5113 genotype COQ7-3HA::TRP1, Gal-YAH1::LEU2 This work 
coq5∆ gal-YAH1 W303 genotype coq5:: HIS3, Gal-YAH1::LEU2 This work 
coq7∆ gal-YAH1 his3, ura3, coq7::KanMX4, Gal-YAH1::LEU2 This work 








C)-p-aminobenzoic acid: To a solution of 300 mg of U-(
13
C)-toluene(3.03 
mmol)  in chloroform (25 mL) were successively added 599 L of 70% HNO3 (2.2 equiv.) 
and 1.014 g (2.2 equiv.) of phosphomolybdic acid. The resulting solution was refluxed for 5 
days then washed with water and dried over Na2SO4. Concentration under vacuum afforded 
327 mg (2.27 mmol,75 %) of nitrotoluene as a mixture of two regioisomers (ortho: para ratio, 
54:46) unseparable by silica gel chromatography and pure enough to be used in the next step 
without further purification. 
1
H NMR (CDCl3)    8.50-8.30 (m, 1H), 7.90-7.50(m, 4H), 7.30-
6.75 (m, 3H), 2.60 (dq, 
2
J 13C-H = 129 Hz, 
3
J 13C-H = 9.3 Hz, 
4
J 13C-H = 5.1 Hz, 
4
J 13C-H = 5.1 Hz, 
3H, ortho isomer), 2.47 (dq, 
2
J 13C-H = 127 Hz, 
3
J 13C-H = 10.2 Hz, 
4
J 13C-H = 5.4 Hz, 
4
J 13C-H = 
5.4 Hz, 3H, para isomer). 
To a solution of 207 mg (1.5 mmol) of U-(
13
C)-nitrotoluene (as a 54:46 mixture of 
ortho and para isomers) in 7 mL of 2% aqueous H2SO4 were successively added 642 mg (2 
equiv.) of NaIO4 and 287 mg (2 equiv.) of LiBr. After 30 hours at 95 °C, 2 additional equiv of 
both NaIO4 and LiBr were added and the resulting solution was stirred for aditionnal 20 hours 
at 95°C. The aqueous solution was then extracted with EtOAc ( 3 times) and the resulting 
organic was successively washed with saturated solution of Na2S2O3, twice with water, brine, 
dried over Na2SO4 then concentrated under vacuum to afford 209 mg (1.24 mmol , 83%) of 
the mixture of ortho and para U-(
13
C)-nitrobenzoïc acid as a pale yellow solid. 
Recristallisation by slow evaporation of diethylether from a solution of the crude product in 
diethylether resulted in the formation of a mixture of two kinds of crystals. Manual separation 
allowed the isolation of 17 mg of pure U-(
13
C)-para- nitrobenzoic acid. 
1
H NMR (CD3OD) 
8.7-8.5 (m, 2H), 8.12-7.95 (m, 2H). 
A suspension of 17 mg (97.7 mol) of U-(13C)-p-nitrobenzoic acid and 5 mg of 10 % 
Pd-C in 2 mL of methanol was purged with hydrogen then vigorously stirred under H2 
atmosphere (1 bar) for two days. After filtration and evaporation of the solvent under vacuum, 
14 mg (97.2mmol, 99 %) of U-(
13
C)-p-aminobenzoic acid were obtained as a pale yellow 
solid and was pure enough to be used without further purification. . 
1
H NMR (CD3OD) 7.75 
(dm, 
2
J 13C-H =  Hz, 2H), 6.72 (dm, 
2




C decoupling NMR spectrum: 
7.63 (d, JAB= 8.1  Hz, 2H), 6.50 (d, JAB=  8.7 Hz, 2H) 
 
Purification of 3-hexaprenyl-4-aminophenol: A total of 130g of Gal-YAH1 cells (wet 
weight) from a culture in SC medium 2%glucose with 10mg/L pABA were used for lipid 
extraction as described above with volumes scaled up accordingly and without addition of Q4. 
The petroleum ether extract (400mL) was dried under vacuum. The extract was resuspended 
in 10mL methanol and lithium perchlorate was added to a final concentration of 40mM. The 
precipitate was eliminated by centrifugation and the product was purified by multiple 
injections on the C18 column using 98% methanol 20mM lithium perchlorate at 0.5mL/min 
with the precolumn electrode set first at -450mV, then at 700mV and finally at -500mV. The 
retention time of the product changed from 10min in the reduced form to 16 min in the 
oxidized form. Finally, the product was injected in its reduced form on the C18 column using 
100% methanol as a mobile phase and collected by monitoring the absorbance at 300nm. The 
pure product was dried under vacuum and resuspended in deuterated methanol for subsequent 
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